Impact of optical tissue clearing on the Brillouin signal from biological tissue samples by Riobóo, Rafael J. Jiménez et al.
Impact of optical tissue clearing on the 
Brillouin signal from biological tissue 
samples 
RAFAEL J. JIMÉNEZ RIOBÓO,1 MANUEL DESCO,2,3,4,5,* AND MARÍA 
VICTORIA GÓMEZ-GAVIRO2,3,4 
1Instituto de Ciencia de Materiales de Madrid ((ICMM), Consejo Superior de Investigaciones 
Científicas (CSIC), C/ Sor Juana Inés de la Cruz, 3, 28049 Madrid, Spain 
2Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Doctor Esquerdo 46, 28007 Madrid, 
Spain 
3Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, 28911 
Leganés, Spain 
4Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 28029 Madrid, Spain 
5Centro de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro, 28029 Madrid, 
Spain 
*desco@hggm.es 
Abstract: Brillouin spectroscopy is a well-established technology in condensed matter 
physics to characterize the mechanical properties of inert materials, and it has been extended 
very recently to the study of biological samples. Transparency is beneficial for samples to be 
properly analyzed by Brillouin spectroscopy. Here, we explored the efficacy of optical tissue 
clearing techniques to improve the acquisition of Brillouin spectra from biological tissues in 
order to analyze their biomechanical properties. We describe the first application of Brillouin 
scattering to optically cleared biological tissues with CUBIC protocol. We conclude that, 
within the range of error, tissue clearing does not modify the mechanical properties of the 
studied biological tissues. 
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement 
1. Introduction 
Brillouin microscopy is a promising non-invasive and non-destructive technology under 
commercial development at present. The technique enables researchers to characterize the 
mechanical properties of both, inert samples and, more recently, biological tissues [1–6]. Non 
transparent samples can limit the possibilities of using Brillouin spectroscopy [7] and 
therefore, the study of biological samples has been limited to cultured cells and naturally 
transparent tissues. 
The study of living biological samples has been made possible with VIPAs (Virtually 
Imaged Phased Arrays), which are new spectrometers that allow fast spectral measurements 
[8]. The mechanical properties of the extracellular matrix, nucleoli and cytoplasm have been 
analyzed in live plant cells [9] and in human umbilical vein endothelial cells with Brillouin 
[10]. In this context, ex vivo human epithelial tissue was the first biomedical application of 
confocal Brillouin and Raman microscopy [3]. In animal models, zebrafish larvae have been 
used to elaborate the mechanical mapping of the spinal cord growth in vivo [11]. 
In addition, the development of Brillouin light scattering microscopy has made it possible 
to bring biomechanics closer to the clinics. Medical diagnostics applications of this new 
technology are being investigated. Clinical trials are already ongoing in the field of 
ophthalmology (ClinicalTrials.gov, Identifier: NCT02118922). Brillouin has also been used 
to demonstrate ability to detect features associated with bacterial meningitis [12]. 
Different optical tissue clearing protocols have been developed recently to obtain 3D 
tissue images at single cell resolution [13,14]. Tissue clearing techniques make the tissues 
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transparent reducing the opacity by lipid removal. Sample opacity considerably limits the 
laser light penetration depth due to differences in the refractive indices in the tissue (opacity 
of the tissue) and the resulting light scattering effects. These limitations are overcome by 
tissue clearing, thereby enabling the study of detailed 3D structures. Micro-Brillouin has been 
applied to mouse brain to analyze amyloid-beta plaques in transgenic animals and in 
Alzheimer's disease brains [6,15]. We analyzed different areas of brain and heart mouse 
samples optically cleared with the CUBIC (clear, unobstructed brain imaging cocktails and 
computational analysis) protocol [16–18] and compared them with uncleared tissue. The aim 
of this work is precisely to show the effects, if any, of the clearing process in Micro-Brillouin 
experiments, which are the key for assessing the elastic properties of biological tissue. Any 
other effects due to the tissue clearing technique have not been addressed. In so far we have 
focused our attention to the position and width of the Brillouin peaks in different samples, 
treated and not treated. We used 20X and 50X magnification objectives to acquire micro-
Brillouin spectra from different regions of the sample. Heart samples showed more 
homogeneity than brain samples even under untreated conditions, but the quality of the 
Brillouin spectrum was further improved after tissue clearing. 
Here we present a novel approach to the study of tissue biomechanical properties that 
combines optical tissue clearing protocols and Brillouin spectroscopy. 
2. Material and methods 
2.1 Biological samples preparation 
Adult male mice (n = 3) were anesthetized with intraperitoneal administration of 80 mg/kg 
and 2 mg/kg of Ketamine/Xylazin, respectively. To obtain the brain and heart tissues, the 
chest cavity of the animal was opened and mice were transcardially perfused with 20 ml of 
ice cold phosphate buffered solution (PBS) followed by 50 ml of 4% paraformaldehyde 
(PFA). Hearts and brains were dissected and post-fixed in 4% PFA at 4°C for at least 12 h 
[19,20]. Then the organs were washed with PBS and cleared with the CUBIC-clearing 
reagents [21]. To clear the mouse brains and hearts, they were immersed in CUBIC clearing 
reagent 1 (R1) for 7 days in a shaker at 80 rpm at 37°C. R1 consists of 2.5 g of urea, 2.5 g of 
N,N,N,N-tetrakis 2-hydroxy-propyl, 25% ethilenediamine and 15% Triton X-100 in 3.5 mL 
of water. After the first three days, R1 was replaced with fresh R1. Then, tissues were washed 
as above with PBS-T (containing 0.1% Triton X-100 and immersed in CUBIC clearing 
reagent 2 (R2) for a maximum of 24 h at 37°C, with shaking at 80 rpm. R2 consists of 5 g of 
sucrose, 2.5 g of urea and 1 g of triethanolamine in 1.5mL of water. The protocol is 
summarized in Fig. 1. 
Uncleared and cleared tissue were sliced transversally into 70 μm cross-sections with a 
vibratome (Campden Instruments). Slices were placed on a microscope slide. DAKO 
mounting solution was applied, and the sample was covered with a coverslip. 
                                                                      Vol. 10, No. 6 | 1 Jun 2019 | BIOMEDICAL OPTICS EXPRESS 2675 
 
Fig. 1. CUBIC protocol for clearing mouse heart and brain. Animals were perfused with 4% 
PFA and brain and heart were dissected out. The CUBIC method was used to clear the tissues 
and a vibratome was used to slice the tissue. On the superior part the steps of the protocol are 
described. The superior pictures represent, on the left, an unclear (left) and cleared (right) 
mouse brain and in the inferior part an unclear (left) and cleared (right) mouse are represent. 
2.2 Brillouin spectroscopy 
High resolution micro-Brillouin spectroscopy (HRmBS) was performed with the aid of a 
home modified reflected light Olympus BX51 microscope with three different objectives: 
X10, X20 and X50. The experimental setup [22] is schematically shown in Fig. 2. Brillouin 
spectra were recorded using a Sandercock 3 + 3 Pass Tandem Fabry-Pérot interferometer as 
Brillouin spectrometer [23] and the monochromatic light source used was a DPPS laser 
working at a wavelength (λ0) of 532 nm. Brillouin microscopy used typically a 1.9 mW laser 
beam to obtain the HRmBS spectra. 
Micro-Brillouin spectroscopy implies that information can be only obtained in 
backscattering geometry, thus being sensitive to the refractive index. An additional drawback 
of the backscattering geometry is that, in principle, there is no coupling with shear acoustic 
modes [24]. The acoustic wave vector for backscattering geometry is q180 = [4 π n] / λ0, and 
hence n-dependent [25]. The hypersonic sound propagation velocity (v) is obtained from the 
relation between the Brillouin frequency shift (f180) and q180, and expressed as v = (2 π f180) / 
q180. Thus, the hypersonic velocity reads: v = f180 λ0 / 2n. It is then straightforward to assess 
the corresponding elastic constant if the mass density of the sample (ρ) and its refractive 
index are known. c = ρ v2.” 
3. Results and discussion 
3.1 CUBIC clearing in brain and cardiac mouse tissue 
Clearing protocols have been optimized to clear whole brain and heart [19–21]. Here, we used 
an optimized CUBIC protocol that partially removes the lipids causing tissue opacity, the 
Reagent 1 being responsible for this effect. How this reagent affects the tissue properties is 
still unclear. The size of the samples is slightly modified by the reagents used but cellular and 
subcellular structure is maintained [19–21] (Fig. 1). It has been described that Brillouin 
measurements depend on the fluid content of the material [26]. As CUBIC protocol removes 
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partially lipids we measured Brillouin frequency of the CUBIC-reagent 1 responsible of that 
with CUBIC-R1 after tissues incubation (Table 1). 
Table 1. Brillouin spectroscopy on clearing reagents. Distilled H2O, fresh Reagent 1 (R1) and 
R1 measurement after heart and brain clearing. 90A scattering geometry and backscattering 
geometry were used simultaneously in order to asses hypersonic sound velocity and refractive 
index [27]. For comparison, the refractive index was also measured with a standard Abbe 
refractometer (nA). 
 f90A (GHz) f180 (GHz) v (m/s) n (Brillouin/nA) 
H2O 4.05 7.49 1522 1.31/1.33 
R1 4.65 9.20 1752 1.40/1.41 
R1 heart 4.66 9.24 1752 1.40/1.41 
R1 brain 4.68 9.29 1760 1.40/1.41 
3.2 Brillouin measurements for cleared tissue 
Since we were interested in changes in the elastic properties of homogeneous tissues, we 
focused our attention onto the differences in Brillouin frequency shift for different areas of 
the studied tissues. Figure 2(a) shows an actual picture of the HRmBS used and Fig. 2(b) 
shows the schematics setup. 
 
Fig. 2. Brillouin spectroscopy set-up. (a) Picture of the Brillouin light scattering apparatus with 
the possibility of performing classical as well as micro Brillouin spectroscopy. (b) Schematics 
of the micro-Brillouin set-up. Laser light is directed into a modified reflected light microscope. 
Backscattered light is collected and the Rayleigh light is chopped with a mechanical shutter in 
order to protect the photomultiplier. 
First, we tested the suitability of the clearing protocols in order to improve the quality of 
the Brillouin peaks in different tissues without altering their elastic response. For this 
purpose, two different microscope objectives were used (X20 and X50). As shown in Figs. 
3(a)-3(f), clearing the brain tissue enabled us to obtain narrower and more intense peaks, 
Table 2. 
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Fig. 3. Effect of brain tissue clearing on Brillouin spectra. (a-c) Optical image (a) and Brillouin 
scattering spectrum (b, c) of uncleared brain sections. (d-f) Optical image (d) and Brillouin 
scattering spectra (e,f) of cleared brain sections. Different colours represent different tissue 
areas as indicated in A, B, C and D. 50X (b, e) and 20X (c, f) objectives were used. 
The spectra are shown in channel number and Brillouin frequency shift. All the 
experimental conditions are the same for all the spectra, thus allowing direct comparison. 
Table 2. Quantifications of Brillouin spectroscopy brain sections. Frequency shift (f) and Half 
Width at Half Maximum (Γ) of the Brillouin peak derived from fit analysis of the spectra in the 
linear scan. NC Non cleared, C: cleared. 
 
A 
f /Γ GHz 
B 
f / Γ GHz 
C 
f / Γ GHz 
D 
f / Γ GHz 
Mean Value 
f / Γ GHz 
NCX20 15.11 /2.5 15.56 /2.44 15.17 /1.81 16.30 /1.60 15.54 /2.08 
CX20 16.13 /0.81 15.20 /0.89 15.17 /0.82 15.57 /0.76 15.52 /0.82 
NCX50 14.53 /2.37 16.26 /1.54 15.82 /1.95 16.21 /1.53 15.71 /1.85 
CX50 16.56 /0.86 15.71 /0.87 15.47 /0.66 15.51 /0.82 15.81 /0.80 
Similarly, clearing cardiac tissue resulted in improved Brillouin signal, as shown in Figs. 
4(a)-4(h) and Table 3. 
                                                                      Vol. 10, No. 6 | 1 Jun 2019 | BIOMEDICAL OPTICS EXPRESS 2678 
 
Fig. 4. Effect of heart tissue clearing on Brillouin spectra. (a-c) Optical image (a) and Brillouin 
scattering spectrum (b, c) of uncleared heart sections. (d-f) Optical image (d) and Brillouin 
scattering spectrum (e, f) of cleared heart sections. Different colors represent different tissue 
areas as indicated in A, B, C and D. 50X (b, e) and 20X (c, f) objectives were used. (g, h) 
Result of a non linear squares fit (red line) of the experimental data (circles) using a simple 
lorentzian function plus a suited background function for the anti-stokes side of the Brillouin 
spectrum. (g) not cleared heart sample tissue and (h) cleared heart sample tissue. 
Table 3. Quantifications of Brillouin spectroscopy heart sections. Frequency shift (f) and Half 
Width at Half Maximum (Γ) of the Brillouin peak derived from fit analysis of the spectra in the 
linear scan. NC Not cleared, C: cleared. 
 
A 
f / Γ GHz 
B 
f / Γ GHz 
C 
f / Γ GHz 
D 
f / Γ GHz 
Mean Value 
f / Γ GHz 
NCX20 17.58 /0.68 17.77 /1.05 16.38 /0.90 17.36 /0.72 17.27 /0.84 
CX20 17.38 /0.76 17.42 /0.65 17.62 /0.64 17.36 /0.71 17.45 /0.69 
NCX50 17.47 /0.68 17.80 /0.82 16.46 /0.83 17.46 /0.69 17.30 /0.75 
CX50 17.34 /0.73 17.28 /0.60 17.69 /0.69 17.28 /0.74 17.40 /0.69 
In a second step, we focused our attention on a defined region of cleared heart tissue in 
order to test the sensitivity of the HRmBS to different regions of the same tissue (Figs. 5(a)-
5(e)). In these experiments only the objective X20 was used. Different regions of heart tissue 
(I and II in Fig. 5(a)) were investigated. These regions are individually shown in Figs. 5(b) 
and 5(c). In region I (Fig. 5(b)), two different measurements were obtained, one from the 
border of the sample (purple circle A, corresponding to the epicardial layer) myocardium) and 
a second one from its the middle (purple circle B, myocardial layer), as depicted in the 
micrograph (objective X20) of Fig. 5(b). In region II (Fig. 5(c)), only one measurement was 
obtained (objective X20), from the inner border of the tissue sample, corresponding to the 
myocardium-endocardium (purple circle in Fig. 5(c)). The obtained HRmBS peaks are shown 
together in Fig. 5(d). Figure 5(e) shows the Anti-Stokes side in order to make the details more 
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visible (lines are only guides to the eyes) and Fig. 5(f) is an example of a typical fit of the 
experimental data. Quantifications of Brillouin spectroscopy of the three different heart layers 
were performed. Frequency shift (f) and half width at half maximum (HWHM) that 
corresponds to the hypersonic attenuation (Γ) of the Brillouin peak were derived from the fit 
analysis of the spectra: A) f = 17.01 ± 0.02 GHz; HWHM = 0.64 ± 0.06 GHz. B) f = 17.39 ± 
0.01 GHz; HWHM = 0.57 ± 0.06 GHz. C) f = 17.51 ± 0.03 GHz; HWHM = 0.67 ± 0.06 GHz. 
 
Fig. 5. Brillouin spectroscopy for different histological layers of the heart. (a) Optical image of 
cleared transversal heart cross-section were acquired with a Stereolupe. (b, c) Magnification of 
the areas I and II respectively and analysed with Brillouin spectroscopy. IA, epicardial layer; 
IB, myocardium; IIC, endocardium. Optical images were acquired with a 20X objective. The 
purple circles represent the area of the scattering volume. These areas result bigger than 
expected due to very high elastic scattering on the tissue surface. (d, e) Brillouin scattering 
spectrum of the three indicated areas in (B) and (C). Different colours represent the different 
tissue areas (A, B and C). (f) Result of a non linear squares fit (red line) of the experimental 
data (circles) using a simple lorentzian function plus a suited background function for the 
stokes side of the Brillouin spectrum of the A region shown in Fig. 5(e). 
These results evidence the power of the HRmBS technique in order to assess differences 
in mechanical properties of different regions of cleared heart tissue. In order to assess the 
homogeneity of these regions, a Brillouin frequency shift map about the epicardial-
myocardial layer was obtained. A region of 50x30 μm2 was mapped in 10 μm steps using the 
X20 microscope objective. The green rectangle in Figs. 6(a) and 6(b) is the mapped zone. To 
enhance the contrast of the micrograph, Fig. 6(a) was obtained using crossed polarizers, while 
Fig. 6(b) was a standard micrograph. The results for the Brillouin frequency shift and 
hypersonic attenuation (Half Width at Half Maximum, HWHM) of the HRmBS peaks are 
summarized in the maps of Figs. 6(c) and 6(d) respectively. Despite the rough resolution of 
the maps, it is very easy to see the frontier between the tissue sample region and the region 
without tissue (brown and black regions in the maps). Inside the tissue, frequency variations 
are small, and in absolute value remain very close to the value obtained in region A (Fig. 
5(b)) and far from the value obtained in region B (Fig. 5(b)). Only two points seem to 
disagree, but is only due to the fact that the HRmBS peak was statistically poor as in the 
scattering volume there was only a small portion of tissue sample and the peak intensity 
obtained was very faint. 
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Fig. 6. Brillouin spectroscopy map of cleared heart sections. (a, b) Optical images of heart 
cross-section with (a) and without (b) crossed polarizers obtained with a 20X objective. (c, d) 
Colour maps showing the spatial distribution of the Brillouin frequency shift and hypersonic 
attenuation of the scanned area respectively. The dimension of the scanned matrix is 50x30 
μm2 with spectra recorded in 10 μm steps and with a 20X objective. Brown and black areas 
indicate the frontier region, in which there were no peaks. The first peak measured was at the 
left inferior corner and the last one was at the right superior corner. 
The HWHM map shown in Fig. 6(d) presents slightly more variability of the experimental 
values, but still within expected range for complex biological tissues. 
4. Conclusion 
In this work we have explored for the first time the combination of optical tissue clearing with 
high resolution micro-Brillouin spectroscopy for biological applications. We found that 
making the tissue transparent by using the CUBIC protocol, the HRmBS peaks clearly 
improved reliability without altering their positions, i.e., the mechanical properties of the 
tissues. Moreover, HRmBS has proven its suitability to detect small changes in mechanical 
properties of biological tissues. The possibility to make biological tissues transparent opens 
new analytical options that may bring biomechanics into the clinic in the future, specifically it 
could be used for the diagnosis of pathological conditions, for example in cardiovascular 
diseases. 
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